Kimberly-Clark Acquires Kenvue in Massive $48.7 Billion Deal
Kimberly-Clark announced on Monday it will purchase Tylenol manufacturer Kenvue in a cash-and-stock transaction valued at approximately $48.7 billion. This landmark deal creates one of the largest consumer health goods companies in the United States.
Key Takeaways
- Deal value: $48.7 billion cash-and-stock transaction
- Creates combined company with ~$32 billion annual revenue
- Kenvue shareholders get $3.50 cash + 0.15 Kimberly-Clark shares per share
- Kenvue shares surged 18% premarket; Kimberly-Clark fell 12.5%
Market Reaction and Company Background
Following the announcement, Kenvue shares jumped 18% in premarket trading while Kimberly-Clark’s stock declined 12.5%. Kenvue had been undergoing strategic review and leadership changes while facing litigation risks and scrutiny after former President Donald Trump’s comments linking Tylenol to autism.
Brand Portfolio and Strategic Implications
The merger combines iconic brands including Neutrogena, Huggies, and Kleenex under a single consumer health and personal care umbrella. The combined entity expects approximately $32 billion in annual revenues.
Kenvue, which was spun off from healthcare conglomerate Johnson & Johnson in 2023, had been exploring strategic options since June when sources indicated the review could include a sale or breakup of the company.
Deal Terms and Valuation
Under the agreement, Kenvue shareholders will receive $3.50 per share plus 0.15 Kimberly-Clark shares for each Kenvue share held. This translates to a per-share value of $21.01 and an equity valuation of $40.32 billion based on Reuters calculations.
